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Abstract: Stem cells originating at fetal age are for many reasons superior as a material for the regenerative medicine purposes,
when compared to their adult counterparts. While hematopoietic cells, isolated from fetal liver or cord blood, have been well
known for a long time and have passed practical tests as clinical transplantation material, the non-hematopoietic cells are newly
recognized, and the knowledge of their phenotype and differentiation potential is rather insufficient. We, and the others, have
identified a subpopulation of cord blood cells phenotypically different from hematopoietic cells (CD34-, CD45-, CD29+, CD44+,
CD51+, CD105+, SH-2, SH-3), in vitro plastic adherent, and capable of multilineage differentiation. The other candidates for
multipotential stem cells are cells extracted from umbilical cord or placental tissue. The preliminary observations suggest, that
these cells, phenotypically similar to the nonhematopoietic cord blood cells, are capable of extensive replication in vitro and
of multilineage differentiation into a variety of tissues including cardiac muscle, bone and cartilage, adipocytes, and nerve
cells. The other possible medical applications include "rejuvenation" of selected tissues and systems in senile patients, and
therapeutical cloning - for both purposes, cells at the fetal stage of genetic regulation may be more useful than cells collected
from adult donors. There is still, however, a high level of uncertainty concerning future medical applications of fetal stem cells.
Their numbers and characteristics may differ from the preliminary observations, and their behavior in vivo may not fulfill the
expectations originating from the in vitro studies. Finally, the autologous applications of stem cells collected at the stage of
birth may need the involvement of technical and financial resources for the storage of frozen cell samples throughout the period
of life of their potential user. Such procedure seems possible from technical point of view, but may be inadequately substantiated
by the eventual advantages.
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Introduction
Stem cells are capable both of self-renewal, and
production of the progeny differentiating into a variety
of tissues - for that reason they are a promising material
for practical clinical applications in so-called "regener-
ative medicine" or "tissue engineering". Both the char-
acteristics, and the numbers of human stem cells vary
depending on the developmental stage of organism, its
age, and the health status. For the practical reasons, the
selection of  stem cells of practical clinical value must
be a compromise between their quality, availability, and
the extent of medical or ethical contraindications based
on the impact of the collection procedure on cell donor.
The most suitable material, considering the biologi-
cal qualities, are embryo stem cells. They are to the
highest extent multipotential (or even totipotential),
have almost unlimited proliferative potential, and (by
therapeutic cloning) they may be almost identical (HLA
compatibility) as patient’s cells. Unfortunately, the at-
tempts to use embryonic cells are (at least currently)
strongly criticized on the ethical basis. There also exists,
although not based on the experimental data, the uncer-
tainty, if the totipotentiality of embryonic stem cells does
not increase the risk of uncontrolled growth and dif-
ferentiation of their progeny in patient’s organism.
Stem cells present in adult organism are at the oppo-
site side of the scale, when compared to embryonic stem
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cells. Their number, already low in the baby, decreases
several logs along with increasing donor’s age. Adult
cells are limited to relatively few ways of differentiation,
and their proliferative potential is low proportionally to
shortening of their telomere lenghts, and inactivity of the
telomerase enzyme. The only hope for widening of
practical clinical applications of adult stem cells is their
putative "plasticity" potential - phenomenon, which
after preliminary enthusiastic recognition is now in-
creasingly questioned.
Stem cells of fetal origin (and collected at the fetal
phase of development, or immediately after, during de-
livery), may be located in the middle between embryonic
and adult stem cells. Although their density in fetal
tissues is much lower than in embryo blastocyst, their
total numbers exceed significantly those of embryonic
origin. Their "quality" measured by the extent of multi-
potentiality is inferior when compared to embryonic
cells, but exceeds significatly that of adult cells - the
longer telomeres, telomerase activity, and much lower
frequency of DNA lesions caused by cell replication and
division events, or environmental mutagens, make fetal
stem cells the "material of choice" for tissue engineering.
Strong argument supporting the importance of fetal stem
cells is complete lack of medical or ethical contraindi-
cations against the collection of those cells which reside
in "waste material" - cord blood, umbilical cord, or
placental tissues.
Human nonhematopoietic stem cells of fetal
origin
For obvious reasons, the cells which are impossible to
collect without causing serious health complications for
the fetus/baby/mother are not considered as interesting
from the practical point of view - this concerns mostly
cells residing in fetal organs (liver, lung, brain, etc.). The
available cell sources are these which do not affect
newborn baby or mother: cord blood (blood residing in
placenta and placental part of umbilical cord after baby’s
delivery), and umbilical cord and placenta themselves.
Nonhematopoietic cord blood stem cells
While cord blood (CB) hematopoietic stem cells are well
characterized, and have been clinically applied for trans-
plantations for almost 20 years, the existence of CB
nonhematopoietic stem cells has been recognized since
a few years [3, 5, 6, 22], and their frequency in cord
blood is still disputable [2, 12, 13]. We, and the others
[1,  3, 7] have detected non-hematopoietic (CD34-,
CD45-), plastic-adherent cells, able to grow without
addition of cytokines in vitro for a period allowing for
over 10 passages. These cells are forming fibroblast-like
plastic-adherent colonies, express on their surface mar-
kers similar to those on adult mesenchymal stem cells
(MSC), and under proper stimulation differentiate into
a variety of tissues (Tab. 1). The ability of these cells to
differentiate towards hematopoiesis is disputable, since it
was confirmed only by one group [12], and not reported
by the other groups investigating their differentiation
potential. Our experience supports the suggestion of in-
ability of MSC-like cord blood cells to differentiate into
hematopoietic cells [3], implying the nonexistence of
"plasticity" phenomenon in our experimental conditions.
When summarizing the "positive reports" concern-
ing the nonhematopoietic stem cells in cord blood, it
seems that these cells are a perfect material for the
future clinical applications. They are not only able to
differentiate into a large variety of tissues in vitro or
in vivo, exceed adult MSC in their proliferative poten-
tial (longer telomeres, telomerase activity), but also
are a unique cell population which may be collected
in good shape (high numbers, high viability, and low
risk of contamination) without any ethical, medical,
or technical problems. Following the optimistic con-
clusions from in vitro observations, preliminary re-
ports confirming the beneficial effects of cord blood
cells in treatment of brain stroke, heart infarct, and
possibly other incurable so far diseases were publish-
ed [9, 10, 28]
The other, however, not so widely recognized re-
ports, are questioning the applicability, or even existence
of nonhematopoietic cord blood cells. Multiple groups
failed to identify these cells in mature delivery cord
blood [8, 15, 16, 25], reported their presence only in
mid-trimester fetal blood [4, 27], or demonstrated the
presence of cells in only small faction of cord blood
collections. In our experience, since detecting by us the
non-hematopoietic CB cells in the year 2000, till now,
we have failed to optimize and improve the method of
their selection and expansion. Several groups reported
the frequency of MSC-like cells in CB samples between
0% and 60% [2, 12, 27], in our experience (unpublished
data), the frequency of MSC-like cells in CB collections
does not exceed 20%. We hypothesize that the low
frequency of the non-hematopoietic cells in CB samples
reflects the biological phenomenon, rather than being an
effect of inadequate research methods. The mechanism
responsible for the phenomenon may be the insufficient
mobilization of these cells during delivery. It can not
also be excluded that the MSC-like cells are naturally
present in circulation in earlier phases of  fetal life only
(an equivalent of hematopoietic cell migration phase?),
and collection of these cells during on-time delivery is
possible only due to the last remnants of these cells
present in small percentage of cases. Irrespective of the
mechanism responsible for the low percentage of CB
samples containing MSC-like cells, this phenomenon, if
confirmed, may substantially reduce the practical im-
portance of CB nonhematopoietic stem cells for clinical
applications.
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Nonhematopoietic stem cells from umbilical
cord or placental tissues
The presence of fibroblast-like cells, extracted from
umbilical cord Wharton’s jelly, and their capability to
grow in vitro in plastic-adherent manner, was described
relatively long time ago [11, 17]. The early finding,
reported and patented [19, 21], was the observation
confirming that these cells are able to differentiate into
cartilage. More recently, cells extracted from Wharton’s
jelly or perivascular region of umbilical cord were re-
ported as multipotential stem cells, capable of differen-
tion into many tissues both in vitro and in vivo [18, 23,
24]. These cells, similarly to CB nonhematopoietic stem
cells, are of fibroblast-like morphology, and both their
phenotype, and the differentiation capabilities, are very
similar to their counterparts present in cord blood (Tab. 2).
The slightly different, than umbilical cord, nonhema-
topoietic stem cell source is also the human placenta - a
successful isolation of such cells from 10 out of 16
specimens (62.5%) was reported [26]. Both umbilical
cord, and fetal-origin tissue from placenta, may be a
source of very similar stem cells - it may be hypo-
thesized, if these cells are migrating from fetal circula-
tion, or are remnants of the stem cells responsible for the
umbilical cord and placenta formation. The phenotype
and differentiation potential of placenta-derived cells
(Tab. 3) do not differ substantially from umbilical cord
or CB cells - the detailed comparison is impossible due
a scarcity of the published data.
Will the nonhematopoietic fetal stem cells
"behave" in future according to the
preliminary hopes?
Currently there is a high dose of official optimism con-
cerning the future medical applications of stem cells in
general, and, among them, the nonhematopoietic fetal
stem cells. These cells, being probably the fetal version
of MSCs residing in adult bone marrow [14, 20], seem
to be capable of multilineage differentiation (at least into
bone, cartilage, hematopoietic microenvironment (adi-
pocytes), muscle, nerve cells (neurons, astrocytes, oli-
godendrocytes), and possibly more other cells and
tissues. The experimental data are, however, prelimi-
nary, mostly deriving from in vitro experiments, and
frequently being obtained rather from the research of
mixed cell populations than of single cells or cell clones.
The other uncertainty results from conclusions drawn
from the analysis of morphology and phenotype of ma-
turing cells, rather than from the analysis of their func-
tions. The early stage of research does not exclude
several risks of incorrect interpretation of the ex-
perimental data: (1) some results may be flawed due to
erroneous interpretation of some cell features (morpho-
logy, markers), and the cells being the object of the study
may not be able to function properly  in vivo; (2) some
effects of in vivo application of stem cells may result not
from proper repair of the injured tissue by the stem cells
themselves, but by regulatory role played by them - this
may not decrease the value of therapy, but may change
the role of the applied stem cells from "tissue producer"
to some kind of "cellular vaccination"; (3) the critical
data concerning stem cell existence, frequency, num-
bers, function, etc., are in some way discriminated - the
common feeling is that authors getting "worse" results
are using "worse" techniques. This "over-enthusiasm",
accompanying regularly all new and important scientific
breakthroughs, needs to take longer time for data verifi-
cation. Finally - if fetal cells have to be used for autolo-
gous treatment, the long-term storage (probably
throughout all the lifetime of their donor) should be con-
Table 1. Characteristics of cord blood MSC-like cells, according to
selected publications
Parameter Characteristics [2, 3, 6, 12, 13]
Morphological 
characteristics
CD14-, CD33-, CD34-, CD45-, CD49-, CD50-,
CD62-, CD106-, CD117-, glycophorin A-,
CD133-, CD135-
plastic-adherent, CD13+, CD29+, CD44+,
CD49+, CD51+, CD73+, CD90/Thy-1+,
CD105/SH-2+, SH-3+, SH-4+, telomeres +++,
telomerase+
Differentiation 
potential
osteogenesis, adipogenesis, chondrogenesis,
neurogenesis (neurons, oligodendrocytes,
astrocytes), myogenesis (myocardium),
hepatocytes (in vivo)*, hematopoiesis*
* reported only by [12]
Table 2. Characteristics of umbilical cord MSC-like cells, according
to selected publications
Parameter Characteristics [17, 18, 22-24]
Morphological 
characteristics
CD34-, CD45-
plastic-adherent, CD29+, CD44+, CD51+,
CD90/Thy-1+, CD105/SH-2+, SH-3+
Differentiation 
potential
osteogenesis, adipogenesis, chondrogenesis,
neurogenesis, myogenesis (myocardium)
Table 3. Characteristics of placental MSC-like cells, according to
selected publications
Parameter Characteristics [26]
Morphological 
characteristics
CD14-, CD34-, CD45-, CD117-, CD133-
plastic-adherent, CD29+, CD44+, CD90/Thy-1+,
CD105/SH2+, SH-3+, SH-4+, ESC-associated
CM+(SSEA-4, TRA-1-60, TRA-1-18)
Differentiation 
potential
osteogenesis, adipogenesis, neurogenesis,
myogenesis (myocardium)
Fetal nonhematopoietic stem cells 211
sidered - the task being technically possible, but disput-
able on the basis of the cost/effect ratio. All the uncer-
tainties mentioned above do not change, however, the
fact, that for many reasons fetal stem cells seem to be
superior to their adult counterparts, and, proportionally
to the overall importance of non-embryonic stem cells,
will play significant role in medical applications.
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